About this trial
The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);
Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;
EGFR gene testing positive, EGFR 19del/L858R mutation;
Receiving postoperative EGFR-TKI targeted adjuvant therapy;
Disqualifiers
Patients negative for EGFR;
Incomplete surgical resection (R1, R2);
Did not receive EGFR-TKI targeted therapy after surgery;
Recurrent or advanced stage patients;
Trial population
Retrospectively included data from 1000 patients diagnosed with stage IB-IIIA invasive lung adenocarcinoma with EGFR mutations who underwent radical surgery from January 2021 to December 2024.
Trial design
Cohort
Retrospective
Treatments tested in this trial
Comprehensive analysis through laboratory tests, imaging techniques, and clinical data
Diagnostic testExtract radiomics features of the tumor and peritumoral regions from preoperative CT images, H\&E-stained digital pathology whole-slide images, and genetic test reports, and integrate them with multidimensional pathological features and gene expression distribution characteristics to construct a radiopathogenomic multi-omics modality, providing more precise prognostic assessment for targeted therapy in lung cancer patients.
Treatment groups
Trial outcomes
Primary outcomes
DFS
The endpoint of this study was disease-free survival (DFS), defined as the time interval from surgery to the first recurrence or death,assessed up to 24 months。
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: